CA2307850A1 - Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire - Google Patents

Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire Download PDF

Info

Publication number
CA2307850A1
CA2307850A1 CA002307850A CA2307850A CA2307850A1 CA 2307850 A1 CA2307850 A1 CA 2307850A1 CA 002307850 A CA002307850 A CA 002307850A CA 2307850 A CA2307850 A CA 2307850A CA 2307850 A1 CA2307850 A1 CA 2307850A1
Authority
CA
Canada
Prior art keywords
substituted
heteroaryl
aryl
previously defined
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002307850A
Other languages
English (en)
Inventor
Yat Sun Or
Jacob J. Plattner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2307850A1 publication Critical patent/CA2307850A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

On décrit un procédé de traitement de tumeurs ou d'une dégénérescence maculaire chez un patient humain ou vétérinaire, qui consiste à administrer un composé sélectionné dans le groupe constitué par les formules (I), (II), (III), (IV), (V), (VI) et (VII). On décrit une composition pharmaceutique contenant un transporteur pharmaceutiquement acceptable ou un composé de ladite composition.
CA002307850A 1997-10-31 1998-10-30 Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire Abandoned CA2307850A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
US08/961,473 1997-10-31
PCT/US1998/023043 WO1999022722A2 (fr) 1997-10-31 1998-10-30 Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire

Publications (1)

Publication Number Publication Date
CA2307850A1 true CA2307850A1 (fr) 1999-05-14

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002307850A Abandoned CA2307850A1 (fr) 1997-10-31 1998-10-30 Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire

Country Status (17)

Country Link
EP (1) EP1027060A2 (fr)
JP (1) JP2001521891A (fr)
KR (1) KR20010031577A (fr)
CN (1) CN1278178A (fr)
AR (1) AR043071A1 (fr)
AU (1) AU1206799A (fr)
BG (1) BG104436A (fr)
BR (1) BR9813318A (fr)
CA (1) CA2307850A1 (fr)
HU (1) HUP0100012A3 (fr)
IL (1) IL135518A0 (fr)
NO (1) NO20002189L (fr)
PL (1) PL340604A1 (fr)
SK (1) SK6172000A3 (fr)
TR (1) TR200001147T2 (fr)
WO (1) WO1999022722A2 (fr)
ZA (1) ZA989885B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248588B2 (en) 2000-04-13 2006-02-02 Biotica Technology Limited Hybrid glycosylated products and their production and use
SI1539157T1 (sl) 2002-09-18 2013-11-29 Trustees Of The University Of Pennsylvania Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
JP4719671B2 (ja) 2003-03-28 2011-07-06 コーネル・リサーチ・ファンデーション・インコーポレイテッド ミグラスタチンアナログ組成物およびその使用
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
CN1950388A (zh) * 2004-02-27 2007-04-18 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
EP2716647A3 (fr) * 2004-02-27 2014-08-20 Rib-X Pharmaceuticals, Inc. Composes Macrocycliques Et Leurs Procedes De Fabrication Et D'utilisation
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
CA2597590A1 (fr) 2005-02-09 2006-08-17 Macusight, Inc. Formulations pour un traitement oculaire
WO2007011880A2 (fr) 2005-07-18 2007-01-25 Minu, L.L.C. Neuro-protection/neuro-stimulation oculaire amelioree
EP1928893A2 (fr) 2005-08-24 2008-06-11 Rib-X Pharmaceuticals, Inc. Composes de triazole et preparation et utilisation de ces composes
EP1934237A2 (fr) 2005-08-24 2008-06-25 Rib-X Pharmaceuticals, Inc. Triazoles et procedes de production et d'utilisation de ces composes
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
KR20010031577A (ko) 2001-04-16
PL340604A1 (en) 2001-02-12
HUP0100012A3 (en) 2003-07-28
JP2001521891A (ja) 2001-11-13
NO20002189L (no) 2000-06-28
NO20002189D0 (no) 2000-04-27
CN1278178A (zh) 2000-12-27
SK6172000A3 (en) 2001-03-12
AU1206799A (en) 1999-05-24
TR200001147T2 (tr) 2000-08-21
HUP0100012A2 (hu) 2001-05-28
WO1999022722A2 (fr) 1999-05-14
BG104436A (en) 2000-12-29
ZA989885B (en) 1999-05-05
EP1027060A2 (fr) 2000-08-16
IL135518A0 (en) 2001-05-20
BR9813318A (pt) 2000-08-22
WO1999022722A3 (fr) 1999-08-05
AR043071A1 (es) 2005-07-20

Similar Documents

Publication Publication Date Title
AU1206799A (en) Use of macrolides for the treatment of cancer and macular degeneration
US5827895A (en) Hexahydrolupulones useful as anticancer agents
EP0483077A2 (fr) Méthode de synthèse d'n médicament contraceptif et régulateur du cycle mentstruel ayant des proprietés oncostatique antikinétosiques, préventives et thérapeutiques, pour le traitement des tumeurs mammaires et des mélanomes.
EP1025114B1 (fr) Derives d'erythromycine cetolides, modifies en n-3' et substitues en o-6, possedant une activite antibacterienne
HU211337A9 (en) 4"-deoxyerythromycin derivatives
CN1269803A (zh) 6,9－桥红霉素衍生物
WO2005007143A2 (fr) Procede pour traiter la tuberculose
EP1167375A1 (fr) Derives d'erythromycine
JPS61251696A (ja) 新規化合物，その製法及びそれを含む医薬組成物
US6034069A (en) 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
JPH07110874B2 (ja) エリスロマイシンａ誘導体
MXPA97008611A (en) Compounds of dialquiltiacumic
US6946446B2 (en) Anti-infective agents useful against multidrug-resistant strains of bacteria
JP2003507487A (ja) 抗菌活性を有する９ａ−アザライド類
WO2002081493A1 (fr) Macrolide 14-elements- 9-amino derive de la leucomycine
CN113116859B (zh) 阿奇霉素丸芯包衣制剂
RU2039560C1 (ru) Вещество, обладающее противоопухолевой активностью
CZ20001524A3 (cs) Farmaceutický přípravek pro léčení nádorů a makulární degenerace
EP1259923B1 (fr) Agents anti-infectieux utiles contre des souches de bacteries resistant a l'action de plusieurs medicaments
US20040220120A1 (en) Novel anhydrolide derivatives having antibacterial activity
US6716820B1 (en) 6-O-substituted bicyclic macrolides
WO2002094183A2 (fr) Methode de traitement d'une tumeur, utilisant des derives de fumagillol
WO2023134707A1 (fr) Méthodes de traitement d'aml-mrc et de mds
US6812216B2 (en) 11-C-substituted derivatives of clarithromycin
US5217960A (en) Erythromycin derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued